P-5115 Pemafibrate, Free Acid, >99%

Synonyms : [K-877] [R-K-13675]

Related Terms : [Parmodia]

New
  • Size
  • US $
  • €
  • £
  • ¥
  • 1 mg
  • 43
  • 41
  • 35
  • 5,900
  • Add to Cart Qty:
  • In stock
  • 5 mg
  • 64
  • 61
  • 53
  • 8,800
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 98
  • 94
  • 81
  • 13,500
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 199
  • 191
  • 165
  • 27,500
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 340
  • 327
  • 282
  • 47,000
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 520
  • 500
  • 432
  • 71,900
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 874
  • 841
  • 727
  • 120,800
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 1,790
  • 1,723
  • 1,489
  • 247,500
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 490.55
  • C28H30N2O6
  • [848259-27-8]

Solubility: DMSO.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Pemafibrate, also known as K-877, is a selective peroxisome proliferator-activated receptor [alpha] (PPAR[alpha]) modulator and a next-generation PPAR[alpha] agonist. It activated PPAR[alpha], PPAR[gamma], and PPAR[delta] with EC50 values of 1 nM, 2.3 uM, and 1 uM, respectivey.  Fruchart J.C.  "Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists."  Cardiovasc Diabetol. 12: 82 (2013).
  • When compared to placebo and fenofibrate, pemafibrate improved triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and other lipid parameters without increasing adverse events or adverse drug reactions in dyslipidaemic patients with high TG and low HDL-C.  Ishibashi S., et al.  "Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial."  Atherosclerosis 249: 36-43 (2016).
  • Pemafibrate suppressed diet-induced obesity; decreased plasma glucose, insulin and TG levels; increased plasma fibroblast growth factor 21 in mice; and improved their obesity-related metabolic abnormalities. Araki M., et al. "The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice." Int. J. Mol. Sci. 19(7): 2148 (2018).
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
1544